4.6 Review

Clostridium difficile Infection: New Insights Into Management

期刊

MAYO CLINIC PROCEEDINGS
卷 87, 期 11, 页码 1106-1117

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2012.07.016

关键词

-

向作者/读者索取更多资源

Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection. (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Gin Proc. 2012:87(11):1106-1117

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据